A Phase Ib/II Study of Orelabrutinib and Sintilimab in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
Latest Information Update: 25 Sep 2021
At a glance
- Drugs Orelabrutinib (Primary) ; Sintilimab (Primary)
- Indications CNS cancer; Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 20 Jul 2021 New trial record